These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28060405)

  • 41. Expression of feline immunodeficiency virus (FIV) gag gene in vaccinia virus vector.
    Wojcik J
    Acta Microbiol Pol; 1995; 44(2):191-6. PubMed ID: 8906935
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D.
    Meseda CA; Stout RR; Weir JP
    Viral Immunol; 2006; 19(2):250-9. PubMed ID: 16817767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.
    Sutter G; Staib C
    Curr Drug Targets Infect Disord; 2003 Sep; 3(3):263-71. PubMed ID: 14529359
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta.
    Peplinski GR; Tsung K; Whitman ED; Meko JB; Norton JA
    Ann Surg Oncol; 1995 Mar; 2(2):151-9. PubMed ID: 7728569
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker.
    Sánchez-Puig JM; Blasco R
    Biotechniques; 2005 Nov; 39(5):665-6, 668, 670 passim. PubMed ID: 16312215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Notes on transient host range selection for engineering vaccinia virus strain MVA.
    Tscharke DC; Smith GL
    Biotechniques; 2002 Jul; 33(1):186-8. PubMed ID: 12139244
    [No Abstract]   [Full Text] [Related]  

  • 47. [A novel system for producing lentiviral vectors].
    Ma Q; Li M; Dong WQ; Wu YS
    Sheng Wu Gong Cheng Xue Bao; 2007 Sep; 23(5):958-60. PubMed ID: 18051882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Construction of recombinant vaccinia virus expressing HSV-2 gD gene as live recombinant vaccine strain].
    Yan H; Rong M; Ruan L; Hou Y; He N; Zhu J
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Mar; 11(1):16-20. PubMed ID: 15619895
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rescue of Sendai Virus from Cloned cDNA.
    Bajimaya S; Hayashi T; Takimoto T
    Methods Mol Biol; 2017; 1602():103-110. PubMed ID: 28508216
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and construction of recombinant vaccinia viruses.
    Broder CC; Earl PL
    Methods Mol Biol; 1997; 62():173-97. PubMed ID: 9108521
    [No Abstract]   [Full Text] [Related]  

  • 51. [Effective method of introducing plasmid DNA into eukaryotic cells by using liposomes for producing vaccinia virus recombinants].
    Slepushkin VA; Bukrinskiĭ MI
    Biull Eksp Biol Med; 1987 Oct; 104(10):478-80. PubMed ID: 2823928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early gene expression of vaccinia virus strains replicating (Praha) and non-replicating (modified vaccinia virus strain Ankara, MVA) in mammalian cells.
    Nemecková S; Hainz P; Otáhal P; Gabriel P; Sroller V; Kutinová L
    Acta Virol; 2001; 45(4):243-7. PubMed ID: 11885931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Methods of isolating and selecting recombinant vaccinia viruses expressing heterogenetic viral antigens].
    Gibadulin RA; Iuferov VP; Lideman LF; Parasiuk NA; Ionova KS
    Vopr Virusol; 1988; 33(4):428-31. PubMed ID: 3057744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Application of real-time PCR to significantly reduce the time to obtain recombinant MVA virus.
    Orlova OV; Glazkova DV; Tsyganova GM; Antoshkina IV; Mintaev RR; Tikhonov AS; Bogoslovskaya EV; Shipulin GA
    J Virol Methods; 2021 Mar; 289():114056. PubMed ID: 33359615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A macrophage fusion assay for rapid screening of cloned HIV-1 Env using dual recombinant vaccinia viruses expressing distinct RNA polymerases.
    Isaacs SN; Yi Y; Singh A; Collman RG
    J Virol Methods; 1999 Aug; 81(1-2):55-61. PubMed ID: 10488761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
    Okeke MI; Okoli AS; Diaz D; Offor C; Oludotun TG; Tryland M; Bøhn T; Moens U
    Viruses; 2017 Oct; 9(11):. PubMed ID: 29109380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Expression of antigens of the tick-borne encephalitis virus by various recombinant variants of the vaccinia virus].
    Khromykh AA; Beliaev AS; Rukavishnikov MIu; Daniliuk NK; Sandakhchiev LS
    Dokl Akad Nauk SSSR; 1990; 310(4):996-9. PubMed ID: 2347288
    [No Abstract]   [Full Text] [Related]  

  • 58. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.
    Wyatt LS; Carroll MW; Czerny CP; Merchlinsky M; Sisler JR; Moss B
    Virology; 1998 Nov; 251(2):334-42. PubMed ID: 9837798
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reverse genetics of coronaviruses using vaccinia virus vectors.
    Thiel V; Siddell SG
    Curr Top Microbiol Immunol; 2005; 287():199-227. PubMed ID: 15609513
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Expression of beta-galactosidase in recombinant nonintegrated plasmids in evaluating the functional activity of vaccinia virus promoters].
    Loparev VN; Chernos VI
    Mol Gen Mikrobiol Virusol; 1987 Nov; (11):34-9. PubMed ID: 3127696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.